Context In the past 10 yr, several agents based on prostate-specific membrane antigen
(PSMA) for positron emission tomography imaging have been introduced in clinical practice …

Prostate-specific membrane antigen PET/CT for primary staging of prostate cancer is
becoming increasingly popular due to simultaneous assessment of whole-body disease …

Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …

Background Prostate-specific membrane antigen (PSMA) positron emission tomography
(PET)/computed tomography (CT) has become an increasingly established imaging …

Background The analysis aimed to compare the radiotracers [68 Ga]-Ga-PSMA-11 and [18
F]-F-PSMA-1007 intraindividually in terms of malignant lesions, mi (molecular-imaging) TNM …

Abstract Introduction [18F] PSMA-1007 has potential advantages over [68 Ga] Ga-PSMA-11,
although limited prospective data evaluating diagnostic performance exist. The aims of this …

Prostate-specific membrane antigen (PSMA) is an important cell-surface imaging biomarker
and therapeutic target in prostate cancer. The PSMA-targeted theranostic 177Lu-PSMA-617 …

18F-PSMA-1007 PET is used in the management of patients with prostate cancer. However,
recent reports indicate a high rate of unspecific bone uptake (UBU) with 18F-PSMA-1007 …

Prostate specific membrane antigen (PSMA) is an attractive target for molecular imaging of
prostate cancer and several other solid tumors because of its overexpression in prostate …

The combination of PET and MRI is one of the recent advances of hybrid imaging. Yet to
date, the adoption rate of PET/MRI systems has been rather slow. This seems to be partially …